29 Advanced Solid Tumors Clinical Trials in Tampa, FL (2026)

Q: How do I join a clinical trial in Tampa?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tampa research site will contact you.

Recruiting Advanced Solid Tumors Studies in Tampa

NCT07070232Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in particip...

Tampa, FLPHASE1980 participantsBioNTech SE

View Study Details

NCT05768139Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

Tampa, FLPHASE1880 participantsEli Lilly and Company

View Study Details

NCT05067283Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified ki...

Tampa, FLPHASE1830 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06983743Recruiting

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. E...

Tampa, FLPHASE1600 participantsErasca, Inc.

View Study Details

NCT06384807Recruiting

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors....

Tampa, FLPHASE1500 participantsBiohaven Therapeutics Ltd.

View Study Details

NCT03093116Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

Tampa, FLPHASE1500 participantsTurning Point Therapeutics, Inc.

View Study Details

NCT07038343Recruiting

Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when admi...

Tampa, FLPHASE1480 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT06051695Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell l...

Tampa, FLPHASE1474 participantsA2 Biotherapeutics Inc.

View Study Details

NCT05932862Recruiting

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of ...

Tampa, FLPHASE1429 participantsExelixis

View Study Details

NCT06625775Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced...

Tampa, FLPHASE1392 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT07193511Recruiting

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when admini...

Tampa, FLPHASE1355 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT05315700Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-...

Tampa, FLPHASE1350 participantsORIC Pharmaceuticals

View Study Details

NCT06952010Recruiting

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s...

Tampa, FLPHASE1303 participantsExelixis

View Study Details

NCT05954312Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab....

Tampa, FLPHASE1290 participantsVividion Therapeutics, Inc.

View Study Details

NCT06227377Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab....

Tampa, FLPHASE1250 participantsQuanta Therapeutics

View Study Details

NCT06234397Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and effic...

Tampa, FLPHASE1245 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT06682793Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head a...

Tampa, FLPHASE1240 participantsA2 Biotherapeutics Inc.

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

Tampa, FLPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT04421820Recruiting

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and...

Tampa, FLPHASE1220 participantsBold Therapeutics, Inc.

View Study Details

NCT06244485Recruiting

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors....

Tampa, FLPHASE1210 participantsDaiichi Sankyo

View Study Details

NCT04981119Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible p...

Tampa, FL200 participantsA2 Biotherapeutics Inc.

View Study Details

NCT04064359Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are norma...

Tampa, FLPHASE1200 participantsOxford BioTherapeutics Ltd

View Study Details

NCT05422911Recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have succe...

Tampa, FLPHASE2192 participantsSun Pharmaceutical Industries Limited

View Study Details

NCT07436728Recruiting

A Study of TAK-505 in Adults With Solid Tumors

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in ...

Tampa, FLPHASE1151 participantsTakeda

View Study Details

NCT06974110Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clini...

Tampa, FLPHASE1132 participantsMOMA Therapeutics

View Study Details

NCT07252479Recruiting

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will help identify doses for use in future testin...

Tampa, FLPHASE1118 participantsAdlai Nortye Biopharma Co., Ltd.

View Study Details

NCT06541262Recruiting

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that h...

Tampa, FLPHASE1104 participantsMilton S. Hershey Medical Center

View Study Details

NCT04890613Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid t...

Tampa, FLPHASE152 participantsSenhwa Biosciences, Inc.

View Study Details

NCT05076760Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 do...

Tampa, FLPHASE140 participantsMemgen, Inc.

View Study Details

About Advanced Solid Tumors Clinical Trials in Tampa

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 29 advanced solid tumors clinical trials recruiting participants in Tampa, FL. These studies are seeking a combined 9,937 participants. Research is being sponsored by BioNTech SE, Eli Lilly and Company, Merck Sharp & Dohme LLC and 22 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Tampa — FAQ

Are there advanced solid tumors clinical trials in Tampa?

Yes, there are 29 advanced solid tumors clinical trials currently recruiting in Tampa, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tampa?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tampa research site will contact you about next steps.

Are clinical trials in Tampa free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tampa studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 29 active trials in Tampa are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 17, 2026 from ClinicalTrials.gov